NCT00965822View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population

PHASE2CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Upper Respiratory Tract Infections
Interventions
OTHER

North American ginseng

3 day, once daily, dosing

OTHER

Placebo

3 day, once daily dosing

Trial Locations (4)

T5N 4A3

Alberta Health Services, Edmonton

E2L4L2

Saint John Regional Hospital, Saint John

B3K 6R8

Canadian Center for Vaccinology, Dalhousie University, Halifax

M4P 1P2

JDM Research, Toronto

Sponsors
All Listed Sponsors
lead

Afexa Life Sciences Inc

INDUSTRY

NCT00965822 - A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population | Biotech Hunter | Biotech Hunter